The ability to directly enhance electrical excitability of human cells is hampered by the lack of methods to efficiently overexpress large mammalian voltage-gated sodium channels (VGSC). Here we describe the use of small prokaryotic sodium channels (BacNav) to create de novo excitable human tissues and augment impaired action potential conduction in vitro. Lentiviral co-expression of specific BacNav orthologues, an inward-rectifying potassium channel, and connexin-43 in primary human fibroblasts from the heart, skin or brain yields actively conducting cells with customizable electrophysiological phenotypes. Engineered fibroblasts (‘E-Fibs’) retain stable functional properties following extensive subculture or differentiation into myofibroblasts and rescue conduction slowing in an in vitro model of cardiac interstitial fibrosis. Co-expression of engineered BacNav with endogenous mammalian VGSCs enhances action potential conduction and prevents conduction failure during depolarization by elevated extracellular K+, decoupling or ischaemia. These studies establish the utility of engineered BacNav channels for induction, control and recovery of mammalian tissue excitability.
Voltage-gated sodium channels (VGSCs) exist in all animal organisms and govern processes fundamental to life including neuronal communication, muscle contractions or hormonal release1. In electrically excitable tissues, VGSCs enable firing and spread of action potentials (APs) and their loss-of-function mutations2 cause a variety of neuronal3,4,5,6, cardiac7,8 and skeletal muscle9,10 disorders. Similarly, acute tissue injuries resulting in permanent excitability loss (for example, stroke, spinal cord injury and heart attack) are associated with long-term disability and death. In addition to excitable tissues, the VGSCs are expressed in many unexcitable cells including macrophages, microglia and islet β-cells, where they play important roles in phagocytosis, migration, insulin secretion and other cellular processes11. The ion-conducting α-subunits of mammalian VGSCs have four structurally homologous domains, each consisting of ∼300 amino acids12. These four domains are simultaneously transcribed and translated from a single, relatively large (>6 kb) gene. This large gene size precludes stable and efficient expression of mammalian VGSCs in primary cells, a strategy that could potentially lead to new remedies for impaired tissue excitability.
The recent discovery of a large bacterial VGSC family (BacNav) has provided novel insights into the structure and biophysical properties of eukaryotic VGSCs13,14,15,16,17. In contrast to their eukaryotic counterparts, BacNav13 consist of four identical domains, individually transcribed and translated from single genes of only ∼900 bp in size. Although the small size of BacNav facilitates their overexpression and purification for crystallography studies18, it is plausible that BacNav genes could be efficiently packaged into viral vectors, either alone or with other ion channel genes, and used to stably introduce or modify electrical excitability of mammalian tissues. Furthermore, utilization of BacNav orthologues with diverse biophysical properties13,14,15,16,19,20, combined with targeted channel mutations, may allow custom engineering of cellular electrophysiological phenotypes tailored to specific tissue types, diseases and individuals.
Here we combined electrophysiological, computational and genetic engineering techniques to establish a versatile BacNav-based platform that enables stable conversion of unexcitable primary human fibroblasts into AP conducting cells that can successfully recover conduction slowing in an in vitro model of cardiac interstitial fibrosis. Moreover, we demonstrate that direct expression of engineered BacNav channels in mammalian excitable cells can enhance their excitability and prevent loss of AP conduction in pathological conditions when endogenous Na+ channels fail to activate.
Genetic engineering of actively conducting human fibroblasts
To stably convert unexcitable primary fibroblasts into actively conducting cells (named engineered fibroblasts or ‘E-Fibs’), we first explored a BacNav variant from Roseobacter denitrificans, NavRosD G217A, shown in our preliminary tests to be capable of generating AP propagation when transfected in a monolayer of HEK293 cells stably expressing Kir2.1 and connexin-43 (Cx43). We generated a high-titre bi-cistronic lentivirus pRRL-CMV-RosDG217A-P2A-eGFP-Kir2.1 encoding both NavRosD G217A and inward-rectifier potassium channel Kir2.1 (gene KCNJ2) fused with enhanced green fluorescent protein (eGFP) (eGFP-Kir2.1), separated by the self-cleaving peptide P2A. Adult human dermal fibroblasts (HDFs) transduced with this virus stably expressed inward-rectifier K+ current, IK1 (Fig. 1a,b), and bacterial Na+ current, INaRosD G217A (Fig. 1c,d), at much higher levels compared with endogenous currents, and exhibited a significantly hyperpolarized resting membrane potential of −78.4±0.2 mV (n=6) compared with that of wild-type (wt)-HDFs (−23.3±2.9 mV; n=5). The resulting voltage dependencies of activation and inactivation of NavRosD G217A (Fig. 1e) in transduced HDFs were similar to those previously reported in transfected HEK293s (ref. 15). Importantly, transduced HDFs became electrically excitable, whereby injection of 1 ms current pulses of increasing amplitude elicited reproducible firing of an ‘all-or-none’ AP (Fig. 1f). These results demonstrated the ability of BacNav to yield creation of de novo electrically excitable cells.
To enable electrical coupling in excitable HDFs, we co-transduced them with a pRRL-CMV-Cx43-P2A-mCherry lentivirus. Transduced cells robustly expressed membrane-bound Cx43 gap junctions (Fig. 1g), which resulted in improved intercellular coupling compared with wt-HDFs as revealed by fluorescence recovery after photobleaching21, albeit not to the same level as measured in neonatal rat cardiomyocytes (Fig. 1h). These engineered HDFs (E-HDFs) were then cultured at confluence in 2 cm diameter monolayers in a random or aligned configuration (Supplementary Fig. 1). When electrically stimulated by a bipolar platinum electrode, randomly oriented E-HDFs supported circular AP spread at an average conduction velocity (CV) of 3.63±0.23 cm s−1 (Fig. 1i and Supplementary Video 1). As expected, aligned E-HDFs exhibited elliptical (anisotropic) AP spread with higher CVs along (3.86±0.14 cm s−1, n=5) versus across (2.07±0.19 cm s−1, n=5) cell orientation (Fig. 1j and Supplementary Video 1). Although the above approach enabled AP propagation in initially unexcitable human fibroblasts, CVs were low, which could be at least in part attributed to the relatively slow activation kinetics of NavRosD G217A.
Improved E-Fib electrical properties with NavSheP mutants
To augment the excitability and conduction of E-HDFs, we developed a combined computational and experimental strategy to screen and identify BacNav variants with more favourable properties (Fig. 2a). We set to explore the BacNav orthologue from Shewanella putrefaciens, NavSheP, for its fast current kinetics15. As the wt NavSheP channel has a highly hyperpolarized voltage dependency of steady-state inactivation, it does not yield AP firing when co-expressed with Kir2.1. We thus proceeded to shift the activation and inactivation curves of NavSheP to more depolarized voltages based on the previous studies of specific residues in NaChBac channels22 and significant homology between different BacNav orthologues (Supplementary Fig. 2); we created a library of NavSheP mutants where either the D60 or E43 residue was substituted with other standard amino acids. These 38 NavSheP mutants were transiently expressed in a monoclonal HEK293 line stably expressing Kir2.1 and the resulting sodium current was recorded by voltage clamp. The E43 mutants exhibited highly depolarized voltage dependence of activation (Supplementary Table 1); therefore, we focused on detailed characterization of D60 mutants. The D60 mutant channels exhibited a wide range of steady-state and kinetic parameters (Supplementary Fig. 3 and Supplementary Table 1) and predominantly exhibited fast kinetics compared with the NavRosD channel (Supplementary Fig. 3c,d and Supplementary Table 1). Based on the recorded parameters, we applied computational modelling to infer AP upstroke, threshold, duration and CV that would result from the same expression level of different NavSheP mutants in an electrically coupled, Kir2.1 HEK293 line (Fig. 2b–e and Supplementary Fig. 4) and constructed NavSheP D60X-Kir2.1 lentiviruses for three D60X mutants (D60A, D60N and D60S) that exhibited the steepest AP upstrokes and highest CVs among different BacNav models. All three mutants exhibited significantly faster kinetics compared with NavRosD G217A in transduced cells (Fig. 2f,g), which allowed generation of APs with shorter duration and sharper upstroke velocity (Fig. 2h–j). Co-transduction of these viruses with Cx43 in HDFs yielded a 2.5-fold improvement in CV compared with the use of NavRosD (Fig. 2k,l and Supplementary Video 2). This demonstrated the potential for combining BacNav mutagenesis and computational modelling, to engineer primary human fibroblasts with desired electrophysiological phenotypes.
Fine-tuning of E-Fib electrical properties via FACS
The use of fluorescence reporters in multi-cistronic lentiviruses (for example, pRRL-CMV-SheP D60N-P2A-eGFP-Kir2.1) allowed us to further vary INaSheP and IK1 levels, and characterize their functional effects on E-HDFs. Using fluorescence-activated cell sorting (FACS), we sorted E-HDFs into three populations with low, medium and high GFP expression levels (Supplementary Fig. 5a), which yielded corresponding low, medium and high levels of IK1 (Fig. 3a) and INaSheP (Fig. 3b), and distinct changes in AP shape (Fig. 3c). Specifically, a trend towards more hyperpolarized resting membrane potential (Fig. 3d, one-way analysis of variance, P=0.15) and the significantly higher maximum upstroke velocity (Fig. 3e) could be attributed to higher IK1 and INaSheP, respectively, whereas the increased APD (Fig. 3f) resulted from net depolarizing effect of increased IK1 and INaSheP on membrane repolarization. Although higher AP upstroke velocities expectedly yielded higher CVs (Fig. 3g,h), this effect was moderate, which we hypothesized was due to simultaneous increase in IK1 along with INaSheP. We thus modelled concurrent increase in IK1 and INaSheP to simulate the experiment (model 1; Supplementary Fig. 6) and compared resulting CVs with those caused by an increase in INaSheP alone (model 2; Supplementary Fig. 6). Despite the same AP upstroke velocities in both models (Supplementary Fig. 6a), CV in model 1 increased less (Supplementary Fig. 6b), because more depolarizing current was needed to overcome high IK1, reach threshold and elicit AP (Supplementary Fig. 6c). Examining a wide range of channel conductances ( and ) further revealed that although threshold current required to elicit AP is primarily sensitive to level of IK1 (Supplementary Fig. 6d), AP upstroke velocity is mainly dependent on INaSheP (Supplementary Fig. 6e), with these two currents inducing opposite effects on CV (Supplementary Fig. 6f). Furthermore, as E-HDFs were also transduced with pRRL-CMV-Cx43-P2A-mCherry lentivirus, sorting cells based on mCherry fluorescence level (Supplementary Fig. 5c) allowed us to vary Cx43 expression and gap junctional coupling of engineered cells. Optical mapping revealed that E-HDFs with higher mCherry/Cx43 expression supported faster AP propagation (Fig. 3i), whereas contrary to eGFP sorting (Supplementary Fig. 5b), mCherry sorting had no effect on APD80 (Supplementary Fig. 5d). Simulation results further revealed that intercellular coupling strength does not influence the relative effects of varying IK1 and INaSheP on CV (Supplementary Fig. 6g).
Robustness of E-Fib electrical phenotype
To test whether E-HDFs can maintain stable electrophysiological phenotype under various perturbations, we expanded them 500-fold over a 4-week period, either directly or after 2 freeze–thaw cycles. In both cases, expanded E-HDFs retained proliferative potential (Fig. 4a) and were able to undergo additional rounds of expansion (for example, 100-fold, 4 passages; Fig. 4b). In addition, as fibroblasts can differentiate into smooth muscle actin expressing myofibroblasts during wound healing and tissue repair23, we treated the expanded E-HDFs with 10 ng ml−1 transforming growth factor-β1 for 7 days, to induce their conversion to myofibroblasts (Fig. 4c,d). Subsequent electrophysiological analysis revealed that despite significant cell expansion or myofibroblast differentiation, the IK1, INaSheP (Fig. 4e,f) and AP characteristics (Fig. 4g–i) of E-HDFs remained unchanged, demonstrating the stability of the acquired functional phenotype. The ability of these cells to undergo repeated freeze–thaw cycles without phenotypic alterations suggested the potential for off-the-shelf delivery applications. Electrophysiological phenotype of E-HDFs remained stable until the cells reached senescence (after additional eight passages and ∼106-fold expansion; Supplementary Fig. 7a–d). Furthermore, using a classical heterologous expression system—monoclonal HEK293 line expressing Cx43, Kir2.1 and NavSheP D60A—stable electrical properties were maintained beyond 20 passages (Supplementary Fig. 7e–g), with cells adapting to higher pacing rates by decreasing APD80 and CV (Supplementary Fig. 7h,i).
Applicability to other sources of human unexcitable cells
To further demonstrate the versatility of this approach, we used the Kir2.1-NavSheP D60N lentivirus to stably convert human ventricular fibroblasts (HVFs), human astrocytes (HAs) and HEK293s into engineered electrically excitable cells (E-HVFs, E-HAs and E-HEK293, respectively). All engineered cell types displayed strong INaSheP and IK1, and fired APs on stimulation (Supplementary Fig. 8). Expression of the Kir2.1 channels hyperpolarized the resting membrane potentials in all transduced cells to a similar value (Fig. 4j), whereas similar INaSheP levels resulted in comparable upstroke velocities (Fig. 4k). Significant differences in AP duration among different cell types (Fig. 4l) could be attributed to differences in their endogenous currents (Fig. 4m) and potentially other differences in epigenetic, posttranscriptional and posttranslational regulation of ion channel expression and function. Collectively, these results confirmed the robustness of the BacNav engineering approach against the starting unexcitable cell phenotype.
E-Fibs improve conduction in model of interstitial fibrosis
To test whether E-Fibs could improve impaired AP conduction in native excitable tissues, we designed a zig-zag micropattern of neonatal rat cardiomyocytes (Fig. 5a and Supplementary Fig. 9a), which mimics the tortuous electrical conduction of cardiac tissue with interstitial fibrosis24,25. The cardiomyocyte zig-zag micropattern displayed normal AP propagation in the longitudinal direction (Supplementary Fig. 9b), but significantly slowed down transverse CV (3.2±0.4 cm s−1; Supplementary Fig. 9c), which was fully rescued (12.0±0.5 cm s−1) by the electrical coupling of actively conducting E-HDFs and cardiomyocytes (Fig. 5b,c, Supplementary Fig. 9g and Supplementary video 3). In contrast, unexcitable wt-HDFs or excitable NavSheP D60A+Kir2.1 HDFs coupled only by endogenous junctions (no Cx43 overexpression) did not alter the transverse conduction (Fig. 5c and Supplementary Fig. 9d,e), whereas unexcitable HDFs with overexpressed Cx43 yielded only a small conduction improvement (to 6.5±0.3 cm s−1; Fig. 5c and Supplementary Fig. 9f). All groups had similar AP durations (Fig. 5d); thus, wavelength differences (Fig. 5e) reflected the differences in CV. Importantly, these studies suggested that slow electrical propagation in cardiac tissues with interstitial fibrosis could be significantly improved if fibroblasts were engineered to actively conduct APs by becoming both excitable and robustly coupled.
BacNav augment and rescue mammalian tissue excitability
Our computational results showed that select BacNav mutant (NavSheP D60A) displayed comparable AP upstroke and slightly lower CV than mammalian Nav1.5 channel in an excitable cell model (Fig. 2d,e), suggesting that in addition to custom design of de novo excitable cells and tissues, BacNav channels could be exploited to directly manipulate or augment26,27 mammalian tissue excitability. Specifically, when lentivirally expressed in cardiomyocyte cultures, NavSheP D60A channels significantly improved CV from 15.9±0.8 to 26.1±0.7 cm s−1 without altering AP duration (Supplementary Fig. 10). Furthermore, expression of BacNav channels could ameliorate reduced cardiac tissue excitability and arrhythmogenic conduction slowing in various pathological conditions (for example, ischaemia, infarction and congenital disease) associated with membrane depolarization and inactivation of Nav1.5 channels2,28,29 or diminished intercellular coupling30,31. For proof-of-concept studies, we used a NavSheP D60A mutant, which exhibits ∼10 mV more depolarized inactivation V1/2 (−76.8 mV) compared with Nav1.5 channel (−87.4 mV) (Fig. 6a,b). Elevating extracellular K+ concentration to depolarize resting potential and inactivate Nav1.5 channels in Ex293 cells (a monoclonal HEK293 line engineered to stably express Kir2.1, Cx43 and Nav1.5 (ref. 32) resulted in conduction failure after addition of as little as 3 mM KCl. In contrast, Ex293 monolayers transduced with the NavSheP D60A lentivirus sustained AP conduction at significantly higher extracellular K+ concentrations (up to 12.4 mM; Fig. 6c). Furthermore, NavSheP D60A expression in Ex293 monolayers subjected to increased doses of gap junctional blocker palmitoleic acid (PA) attenuated conduction slowing and prevented conduction block at 60 μM PA when cells expressing only Nav1.5 channel failed to conduct (Fig. 6d). Finally, we tested whether viral expression of NavSheP D60A could increase the resistance to conduction failure in cardiomyocyte cultures that underwent regional ischaemia after being covered with a glass coverslip33 (Fig. 6e). During ischaemia, cardiomyocytes exhibited gradual conduction slowing (Fig. 6f,g) and APD shortening (Supplementary Fig. 11a,b), followed by the partial (Supplementary Fig. 11c) and eventually complete conduction block (Fig. 6h and Supplementary Video 4). Importantly, NavSheP D60A expression preserved cell excitability to significantly prolong the time to conduction block (from 10.5±1.0 min in control to 14.2±0.7 min in BacNav-expressing cardiomyocytes; Fig. 6i).
Since their discovery 15 years ago13, prokaryotic Na+ channels have contributed greatly to understanding structure16,20, function34,35 and pharmacology36 of the more complex eukaryotic VGSCs. Yet, it has remained unexplored if large diversity and small gene size of BacNav could be employed to stably modify and augment the excitability of mammalian tissues, a feat difficult to achieve using large mammalian VGSCs. In this study, we presented a combined experimental and computation strategy for use of BacNav channels in the de novo induction and control of mammalian tissue excitability. Our goal was to develop a versatile platform that would be cost-effective, applicable to a variety of cell types and amenable to rapid production of large quantities of excitable cells for off-the-shelf use.
Previously, we applied a non-viral stepwise expression of cardiac Na+ channel Nav1.5, inward rectifier K+ channel Kir2.1 and gap junctional protein Cx43, combined with antibiotic selection, to generate a stable monoclonal HEK293 line capable of active AP conduction32. Other proof-of-concept studies applied adenoviral expressions of mammalian VGSCs to induce or modify excitability in primary tissues37,38,39; however, these effects were transient and unsuitable for long-term studies or the development of antiarrhythmic gene therapies38,39. Although the use of split-intein-mediated protein trans-splicing strategy40 might be adapted in the future to induce stable expression of mammalian VGSCs in primary cells, efficacy of this approach may be limited due to the need for co-transduction of two or more viruses to reconstitute functional channels. To circumvent the need for expressing large mammalian VGSCs, we exploited much smaller BacNav genes and designed high-titre multi-cistronic lentiviruses coding minimum sets of ion channels required for stable and efficient induction of excitability in primary cells. In fact, using BacNav+Kir2.1 lentiviruses, human and rodent fibroblasts were routinely transduced with 90% efficiency without any loss of cell viability (not shown). Including a fluorescent reporter in the same virus allowed us to further purify transduced cells and fine-tune their electrical properties (Fig. 3 and Supplementary Fig. 5).
Importantly, lentivirally expressed ion currents in all engineered fibroblasts were much larger than their endogenous currents (Fig. 1). As such, resulting electrophysiological phenotype of engineered cells was relatively insensitive to the cell’s epigenetic state and both predictable in silico and for the most part reproducible among different cell types in vitro (Fig. 4j–l and Supplementary Fig. 8). The ability to generate actively conducting HVFs, in particular, suggested a potential therapeutic strategy whereby in situ fibroblast engineering could improve impaired conduction in fibrotic heart tissues. As a proof of concept, we showed that well-coupled and excitable (but not weakly coupled and/or unexcitable) fibroblasts successfully restored normal neonatal rat cardiomyocyte conduction in an in vitro model of interstitial fibrosis (Fig. 5). On the other hand, distinct forms of cardiac fibroses, differing in size, and cellular and non-cellular components can result from various types of heart disease or injury41. In situ engineering of actively conducting fibroblasts, while potentially beneficial in improving cardiac conduction in small regions of interstitial or diffuse fibrosis where these cells come in close contacts with cardiomyocytes, may not prove as effective in large cardiac scars with low cellularity. Of note is also that without the prominent Ca2+ currents, engineered fibroblasts are unlikely to spontaneously fire APs or be a source of triggered activity, which could potentially make them less arrhythmogenic compared with the use of pluripotent stem cell-derived cardiomyocytes42,43.
Furthermore, transduction of mammalian excitable tissue cultures with specific BacNav mutants augmented or rescued conduction in healthy (Supplementary Fig. 10) and pathological (depolarization, decoupling and ischaemia; Fig. 6 and Supplementary Fig. 11) conditions, suggesting that BacNav-based gene therapies could be targeted directly to excitable cells. In addition, previous studies have shown that BacNav could be converted into Ca2+-selective channel (BacCav) by substituting three amino acid residues of the selectivity filter with Aspartate19,44,45. Hence, stable expression of engineered BacNav channels or their Ca2+-selective derivatives may enable direct therapeutic effects on excitable and unexcitable cells whose function relies on voltage-gated Na+ or Ca2+ channels.
Although in this study we focused on altering specific amino acid residues (E43 or D60) in a particular BacNav orthologue (NavSheP), various combinations of other BacNav orthologues and residues18,46,47 could be explored to customize phenotype of engineered or native excitable cells. For example, mutations in the ‘glycine hinge’ region in some BacNav orthologues could change channel inactivation rate15, and along with tuning of Kir2.1 expression via an independent promoter, could be used to control AP duration to avoid arrhythmogenic dispersion of refractoriness if E-Fibs were used for cardiac cell or in situ gene therapy. Furthermore, replacing the highly conserved negative residues (E70 and D91) of BacNav voltage-sensitive domain with positively charged residues could shift activation to more hyperpolarized voltages48 and be used to reduce AP threshold. Similarly, substituting the negatively charged residues in the neck region of the carboxy-terminal domain (CTD) of the BacNav channel into glycine could destabilize the helix conformation of this region, decrease the depolarization energy required for channel opening49 and further augment cell excitability and conduction. Furthermore, a recent study by Arrigoni et al.50 showed that BacNav CTD plays a critical role in voltage dependence of activation, suggesting CTD swapping among different orthologues could provide yet another method to control excitability of engineered cells.
Basic studies in ‘lower’ organisms, including prokaryotes, have led to versatile approaches to manipulate and study mammalian biology. Recent examples include optogenetics51 and genome-editing techniques52 that, in addition to becoming powerful research tools, have been extensively investigated for potential medical applications. In line with these undertakings, our work supports expansion of prokaryotic ion channel research to basic studies of mammalian tissue excitability and development of new human therapies.
Screening of bacterial sodium channels
To engineer excitable cells, we first explored use of NaChBac channel, the longest studied BacNav orthologue13,17,45,53. However, its slow recovery from inactivation yielded excitable cells with very low maximum capture rate (<1 Hz). This prompted us to instead use NavRosD G217A and NavSheP channels that were kindly provided by Dr Katsumasa Irie from Kyoto University15. Libraries of SheP(D60X) and SheP(E43X) mutants were generated using Quikchange II XL Site-Directed Mutagenesis Kit (Agilent Technologies), as per the manufacturer’s instructions. All the primers used are listed in Supplementary Table 2. Each gene was subcloned into the mammalian expression vector pCMV5(CuO)-IRES-GFP (Qbiogene) and transfected into HEK293 cells stably expressing Kir2.1 using Lipofectamine 2000 transfection reagent (Life Technologies). GFP fluorescence was usually detected after 12 h and cells were patch clamped 24 h after transfection, to derive AP parameters.
Lentiviral plasmids were constructed from the pRRL-CMV vector (a gift from Dr Inder Verma, Salk Institute). BacNav (NavRosD G217A or NavSheP mutant, without a stop codon) was ligated with eGFP-Kir2.1 (Kir2.1 fused with eGFP at the amino terminus) via the viral P2A peptide54 before being subcloned into pRRL-CMV, to create the bi-cistronic lentiviral plasmid pRRL-CMV-BacNav-P2A-eGFP-Kir2.1. To enhance gap junction expression in engineered cells, Cx43 (ref. 32) was linked with mCherry via P2A and subcloned into the pRRL-CMV lentiviral plasmid (pRRL-CMV-Cx43-P2A-mCherry). In the main text, BacNav-Kir2.1 and Cx43 lentiviruses refer to pRRL-CMV-BacNav-P2A-eGFP-Kir2.1 and pRRL-CMV-Cx43-P2A-mCherry virus, respectively. Other lentiviral constructs used in the study were pRRL-CMV-BacNav-P2A-Kir2.1-T2A-eGFP and pRRL-CMV-BacNav-T2A-eGFP. High-titre lentiviruses were produced using second generation lentiviral packaging system. Briefly, 293FT cells (Life Technologies, R700-07) were co-transfected with lentiviral plasmid, packaging plasmid psPAX2 and envelope plasmid pMD2.G (2:1:1 mass ratios) using Lipofectamine 2000 (Life Technologies). Supernatant containing lentiviral particles was collected 72 h after transfection, centrifuged (500 g, 10 min) and filtered through 0.45 μm cellulose acetate filter (Corning) to remove cell debris before combined with Lenti-X Concentrator (Clontech) at 3:1 volume ratio for overnight incubation at 4 °C. Concentrated lentiviral particles were harvested following 45 min centrifugation (1,500 g, 4 °C) and resuspended in 1/10 to 1/100 of the original volume in DMEM medium. Plasmids psPAX2 and pMD2.G were obtained from Didier Trono (Addgene plasmids #12260 and #12259).
Generation of engineered human fibroblasts
Primary adult HDFs (Gibco, C-013-5C) were co-transduced with BacNav-Kir2.1 and Cx43 lentiviruses at a density of 104 cells per cm2 in fibroblast basal medium (ATCC, PCS-201-030). Five days after lentiviral transduction, GFP+/mCherry+ cells were sorted by FACS analysis, replated in fibroblast growth medium (basal medium supplemented with fibroblast low-serum growth kit, ATCC, PCS-201-041) and assessed with patch-clamp recordings and optical mapping at 1 week and 4 weeks after sorting. Conversion of HDFs into myofibroblasts was induced by adding transforming growth factor-β (10 ng ml−1) into culture media for 5 days. Similar lentiviral transduction protocol was repeated in HVFs (Lonza, CC-2904), HAs (Lonza, CC-2565) and HEK293 cells (ATCC, CRL-1573).
Isotropic and anisotropic monolayers of HDFs
E-HDFs were seeded onto 22 mm-diameter Aclar (Electron Microscopy Sciences) coverslips coated with fibronectin (Sigma, 15 μg ml−1, 30 min) at a density of 5 × 104 cells per cm2 to form isotropic monolayers. Anisotropic E-HDF monolayers were formed on Aclar coverslips microcontact printed with a pattern of parallel fibronectin lines (10 μm width, 10 μm spacing) as previously described55. Cells were cultured for 24 h to become confluent and form intercellular junctions followed by optical mapping of AP propagation and immunostaining.
Micropatterned zig-zag cultures
All animals were treated in accordance with protocols approved by the Duke University Institutional Animal Care and Use Committee. Neonatal rat cardiomyocytes were enzymatically dissociated from ventricles of 2-day-old Sprague–Dawley rats and enriched using differential pre-plating56. Specifically, ventricles were excised, minced and incubated with 0.1% trypsin overnight and dissociated in four sequential steps using 0.1% collagenase. Isolated cells were centrifuged (5 min, 200 g) and further enriched by two 45 min pre-plating steps to select for cardiomyocyte-enriched cells that remained unattached after the second pre-plating. Zig-zag cultures were generated as previously described25. Briefly, Aclar coverslips (22 mm diameter) were coated with 5 μg ml−1 collagen I (rat tail, BD Biosciences) for 30 min, rinsed with PBS, then micro-contact printed with a zig-zag network of fibronectin (100 μm-wide lines spaced 100 μm apart and connected by 100 μm-wide transverse bridges staggered every 6 mm). Cardiomyocytes were seeded at a density of 2 × 105 cells per cm2 in DMEM/F-12 medium (Gibco, 11320-033) supplemented with 10% calf serum and 10% horse serum, followed by a switch to 5% fetal bovine serum media at culture day 2. The following day, E-HDFs were added to the cardiomyocyte zig-zag cultures at a density of 2.5 × 104 cells per cm2. On day 5, co-cultured monolayers were assessed for AP propagation by optical mapping and subsequently fixed for immunostaining.
Cell monolayers or tissue patches were fixed in 2% paraformaldehyde (15 min), permeabilized in 0.5% Triton-X (30 min) and blocked in a 5:1 solution of 1% BSA and chicken serum (30 min). The following primary antibodies (1 h incubation) were used: anti-sarcomeric α-actinin (Sigma, a7811, 1:200), anti-Cx43 (Life Technologies, 71-0700, 1:100), anti-vimentin (Sigma, v6630, 1:500), anti-smooth muscle actin (Sigma, a2547, 1:200), anti-GFAP (BD Biosciences, 561483, 1:100) and anti-Ki67 (Abcam, ab15580, 1:200). Secondary antibodies (1 h incubation) included the following: Alexa488 (Life Technologies, A-21200 or A-21441, 1:200), Alexa594 (Life Technologies, A-21201 or A-21442, 1:200), Alexa647 (Life Technologies, A-21463, 1:200), Alexa488-conjugated phalloidin (Life Technologies, A12379, 1:300) and 4,6-diamidino-2-phenylindole (Sigma, 1:300). All immunostaining steps were performed at room temperature. Fluorescence images were acquired using inverted fluorescence (Nikon TE2000) or confocal (Leica SP5) microscope and processed with ImageJ software.
Fluorescence recovery after photobleaching
Functional coupling in wt and Cx43-expressing HDFs was assessed using fluorescence recovery after photobleaching21,57 as previously described58. Briefly, confluent HDF monolayers were stained with Calcein AM dye (Molecular Probes, 0.5 μM in DMEM) for 20 min at 37 °C, washed with PBS and immersed again in fresh media. The target cell was photobleached with a 488 nm Argon laser and subsequently imaged every 15 s for 6 min using an upright confocal microscope (Zeiss, LSM 510). The level of fluorescence in the target cell was normalized to the fluorescence level in remote unbleached cells and plot as a function of time post photobleaching.
Whole-cell patch-clamp recordings
Cells were briefly trypsinized, plated onto poly-L-lysine-coated glass coverslips and left to attach for 5 h. Cells were then transferred to a patch-clamp chamber perfused with Tyrode’s solution containing (in mM): 135 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 0.33 NaH2PO4, 5 HEPES and 5 glucose. Patch pipettes were fabricated with tip resistances of 1–2 MΩ when filled with pipette solution consisting of (in mM): 140 KCl, 10 NaCl, 1 CaCl2, 2 MgCl2, 10 EGTA, 10 HEPES and 5 MgATP. Whole-cell voltage-clamp and current-clamp recordings were acquired at room temperature (25 °C) and 37 °C, respectively, using the Multiclamp 700B amplifier (Axon Instruments), filtered with a 10-kHz Bessel filter, digitized at 40 kHz and analysed using WinWCP software (John Dempster, University of Strathclyde). To measure BacNav activation properties, membrane voltage was stepped from a holding potential of −100 mV to varying 500 ms test potentials (−50 to 60 mV, increments of 10 mV). Inactivation of BacNav was derived from peak currents measured at 0 mV after varying 3 s prepulse potentials (−160 to −30 mV, increments of 10 mV). For the channels with more hyperpolarized activation and inactivation (NavSheP WT and D60E), holding voltage for steady-state activation protocol was set at −160 mV, whereas steady-state inactivation protocol included prepulse potentials from −180 mV to −30 mV. Steady-state IK1–V curve was constructed from the current responses to varying 1 s test potentials (−130 to 50 mV, increments of 10 mV) from a holding potential of −40 mV. APs were elicited by injecting a 1 ms current pulse at 1.1 × threshold amplitude.
Optical mapping of AP propagation
Cell monolayers or zig-zag cultures were optically mapped with a 20 mm diameter hexagonal array of 504 optical fibres (Redshirt Imaging), as previously described32,55,56. Specifically, cultures were stained with a voltage-sensitive dye (Di-4-ANEPPS, 10 μM) for 5 min at room temperature, transferred to a recording chamber filled with Tyrode’s solution at 37 °C and illuminated by a solid-state excitation light source (Lumencor, SOLA SM) filtered through a 520±30 nm bandpass filter. Emitted red fluorescence signals (λ>590 nm) were collected by the optical fiber array, converted to voltage signals by photodiodes and recorded at a 2.4 kHz sampling rate with a 750 μm spatial resolution. AP propagation was triggered by a 10 ms, 1.2 × threshold, 1 Hz stimulus from either a bipolar point electrode (in isotropic or anisotropic monolayers of E-HDFs) or a line electrode (in the zig-zag cultures). Generation of isochrone maps and calculation of CV, AP duration at 80% repolarization (APD80) and impulse wavelength were performed using custom MATLAB software, as previously described59,60.
Depolarization and decoupling studies
Similar to previous studies61, membrane depolarization in Ex293 monolayers was induced by applying increasing doses of KCl (in 1 mM increments starting from 5.4 mM). After 5 min equilibration at each KCl dose, cells were paced at 1 Hz and AP conduction optically mapped. For gap junction decoupling studies, PA (Sigma, 76168) was dissolved in dimethyl sulfoxide and sonicated (10 min, 37 °C) to yield a stock concentration of 50 mM. Ex293 monolayers were exposed to increasing doses of PA (0, 20, 40 and 60 μM) and after 15 min equilibration at each dose, cells were paced at 1 Hz and AP conduction optically mapped.
Regional ischaemia studies
Regional ischaemia in neonatal rat cardiomyocyte monolayers was induced as described previously33,62. Briefly, 12 mm round glass coverslip was placed onto the central area of a 22 mm cardiac monolayer to induce regional ischaemia. Cells were continuously paced at 1 Hz and AP conduction optically mapped every 1 min during ischaemia, until complete conduction failure in the ischaemic region. CV, APD80 and optical AP amplitude measured at the recording sites of the central ischemic region were normalized to corresponding baseline values before ischemia. Recording site was defined as inactive (not conducting) if its AP amplitude failed below 10% of baseline value.
Experimentally derived modelling parameters are listed in Supplementary Table 3. The AP generation in HEK293 cells co-expressing Kir2.1 and BacNav channels was simulated using the Hodgkin–Huxley formalism63 and the following differential equation:
where V is the cell transmembrane potential, Cm is the total membrane capacitance, INa is the BacNav channel current, IK1 is the inward-rectifier potassium current, Iendo is the endogenous background current and Istim is the stimulus current. Based on the similarities between BacNav and mammalian Cav channels13,45, the BacNav conductance was modelled as a simple product of activation and inactivation gating variables and INa was expressed using the following equation:
where is the maximum conductance of the BacNav channel, m and h are the first-order activation and inactivation gating variables, respectively, and ENa is the sodium Nernst potential given in Supplementary Table 3. Mathematical model of human Nav1.5 was adopted from a previous model of human ventricular tissue64 with a slightly modified inactivation time constant to better fit voltage clamp recordings in Nav1.5-expressing HEK293 cells.
From the voltage-clamp activation and inactivation protocols, the steady-state values of the gating variables as a function of V were plotted and fit to the Boltzmann equation63, to derive the midpoint voltage and slope factor listed in Supplementary Table 1:
The initial and late phases of INa traces for each clamp potential were fit as single exponentials to derive time constants of activation (τm) and inactivation (τh) as functions of V. The τm and τh at V=+20 mV are listed in Supplementary Table 1.
Voltage-clamp recordings of inward-rectifying potassium current were used to fit steady-state IK1 values to a time-independent Nygren et al.65 model as follows:
where is the maximum conductance of the Kir2.1 channel and EK is the potassium Nernst potential given in Supplementary Table 3.
Finally, the endogenous background current of wt HEK293 or HDF cells, Iendo (in pA), was fit by a time-independent linear equation:
where V is given in millivolts. Simulations of single-cell APs for different BacNav mutants were performed using constant and values (measured by patch clamp in a monoclonal HEK293 line expressing Kir2.1, Cx43 and NavSheP D60A; Supplementary Table 3), to allow direct comparisons of how kinetic properties of BacNav on their own affect AP characteristics (upstroke velocity, APD80 and threshold potential). As the whole-cell voltage clamp recordings were performed at 25 °C, to model AP generation at 37 °C, we scaled up EK and ENa from Supplementary Table 3 by 310.15 °K/298.15 °K and further scaled INa, IK1 and Iendo using Q-values of 2.7, 1.8 and 2.1, respectively.
where Δt and Δx are the time (index i) and space (index j) discretization steps, respectively, cm is the specific membrane capacitance, a is the cable radius, Ri is the intracellular resistivity, and is the total ionic current density (in pA cm−2), calculated by dividing the total ionic current from equation (1) with total membrane surface area. The Ri value was adopted to simulate the mean CV measured in optically mapped monolayers of a monoclonal HEK293 line expressing Kir2.1, Cx43 and NavSheP D60A. All simulations were performed with the identical model parameters given in Supplementary Table 3 and distinct kinetic properties measured in different BacNav mutants (adjusted to 37 °C as described above).
The total length of the simulated cable was 0.72 cm (that is, 300 nodes). The first three nodes in the cable were stimulated by current injection (1.2 × threshold) at 1 Hz rate and activation time at each node was determined as the time of maximum upstroke velocity of propagated AP. Inverse slope of activation time versus distance line fit in the central 0.24 cm of the cable was used to calculate CV.
All data are presented as mean±s.e.m. and statistical significance was determined by one-way analysis of variance, followed by Tukey’s post-hoc test to calculate P-values. Statistical significance was defined as ^P<0.05, #P<0.01 and *P<0.0001.
All data supporting the findings of this study are available within the article and its Supplementary Information files or can be requested from the authors.
How to cite this article: Nguyen, H. X. et al. Engineering prokaryotic channels for control of mammalian tissue excitability. Nat. Commun. 7, 13132 doi: 10.1038/ncomms13132 (2016).
Catterall, W. A., Goldin, A. L. & Waxman, S. G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57, 397–409 (2005).
George, A. L. Jr Inherited disorders of voltage-gated sodium channels. J. Clin. Invest. 115, 1990–1999 (2005).
Weiss, J. et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature 472, 186–190 (2011).
Lossin, C. et al. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J. Neurosci. 23, 11289–11295 (2003).
Kamiya, K. et al. A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline. J. Neurosci. 24, 2690–2698 (2004).
Sanders, S. J. et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485, 237–241 (2012).
Kapplinger, J. D. et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 7, 33–46 (2010).
Hu, D. et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J. Am. Coll. Cardiol. 64, 66–79 (2014).
Jurkat-Rott, K. et al. Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc. Natl Acad. Sci. USA 97, 9549–9554 (2000).
Bulman, D. E. et al. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology 53, 1932–1936 (1999).
Black, J. A. & Waxman, S. G. Noncanonical roles of voltage-gated sodium channels. Neuron 80, 280–291 (2013).
Catterall, W. A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26, 13–25 (2000).
Ren, D. et al. A prokaryotic voltage-gated sodium channel. Science 294, 2372–2375 (2001).
Koishi, R. et al. A superfamily of voltage-gated sodium channels in bacteria. J. Biol. Chem. 279, 9532–9538 (2004).
Irie, K. et al. Comparative study of the gating motif and C-type inactivation in prokaryotic voltage-gated sodium channels. J. Biol. Chem. 285, 3685–3694 (2010).
Payandeh, J., Scheuer, T., Zheng, N. & Catterall, W. A. The crystal structure of a voltage-gated sodium channel. Nature 475, 353–358 (2011).
Charalambous, K. & Wallace, B. A. NaChBac: the long lost sodium channel ancestor. Biochemistry 50, 6742–6752 (2011).
Payandeh, J. & Minor, D. L. Jr Bacterial Voltage-Gated Sodium Channels (BacNas) from the Soil, Sea, and Salt Lakes Enlighten Molecular Mechanisms of Electrical Signaling and Pharmacology in the Brain and Heart. J. Mol. Biol. 427, 3–30 (2014).
Shaya, D. et al. Voltage-gated sodium channel (NaV) protein dissection creates a set of functional pore-only proteins. Proc. Natl Acad. Sci. USA 108, 12313–12318 (2011).
Zhang, X. et al. Crystal structure of an orthologue of the NaChBac voltage-gated sodium channel. Nature 486, 130–134 (2012).
Wade, M. H., Trosko, J. E. & Schindler, M. A fluorescence photobleaching assay of gap junction-mediated communication between human cells. Science 232, 525–528 (1986).
Shimomura, T., Irie, K., Nagura, H., Imai, T. & Fujiyoshi, Y. Arrangement and mobility of the voltage sensor domain in prokaryotic voltage-gated sodium channels. J. Biol. Chem. 286, 7409–7417 (2011).
Martin, P. Wound healing--aiming for perfect skin regeneration. Science 276, 75–81 (1997).
de Bakker, J. et al. Slow conduction in the infarcted human heart. ‘Zigzag’ course of activation. Circulation 88, 915–926 (1993).
Kirkton, R. D. & Bursac, N. Genetic engineering of somatic cells to study and improve cardiac function. Europace 14, (Suppl 5): v40–v49 (2012).
Lin, C. W. et al. Genetically increased cell-intrinsic excitability enhances neuronal integration into adult brain circuits. Neuron 65, 32–39 (2010).
Bando, Y. et al. Control of spontaneous Ca2+ transients is critical for neuronal maturation in the developing neocortex. Cereb. Cortex 26, 106–117 (2014).
Janse, M. J. & Wit, A. L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol. Rev. 69, 1049–1169 (1989).
Carmeliet, E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol. Rev. 79, 917–1017 (1999).
Severs, N. J., Bruce, A. F., Dupont, E. & Rothery, S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc. Res. 80, 9–19 (2008).
Danik, S. B. et al. Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ. Res. 95, 1035–1041 (2004).
Kirkton, R. D. & Bursac, N. Engineering biosynthetic excitable tissues from unexcitable cells for electrophysiological and cell therapy studies. Nat. Commun. 2, 300 (2011).
de Diego, C. et al. Electrophysiological consequences of acute regional ischemia/reperfusion in neonatal rat ventricular myocyte monolayers. Circulation 118, 2330–2337 (2008).
McCusker, E. C. et al. Structure of a bacterial voltage-gated sodium channel pore reveals mechanisms of opening and closing. Nat. Commun. 3, 1102 (2012).
Bagneris, C., Naylor, C. E., McCusker, E. C. & Wallace, B. A. Structural model of the open-closed-inactivated cycle of prokaryotic voltage-gated sodium channels. J. Gen. Physiol. 145, 5–16 (2015).
Bagneris, C. et al. Prokaryotic NavMs channel as a structural and functional model for eukaryotic sodium channel antagonism. Proc. Natl Acad. Sci. USA 111, 8428–8433 (2014).
Hou, L., Hu, B. & Jalife, J. Genetically engineered excitable cardiac myofibroblasts coupled to cardiomyocytes rescue normal propagation and reduce arrhythmia complexity in heterocellular monolayers. PLoS ONE 8, e55400 (2013).
Lau, D. H. et al. Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study. Circulation 119, 19–27 (2009).
Boink, G. J. et al. HCN2/SkM1 gene transfer into canine left bundle branch induces stable, autonomically responsive biological pacing at physiological heart rates. J. Am. Coll. Cardiol. 61, 1192–1201 (2013).
Subramanyam, P. et al. Manipulating L-type calcium channels in cardiomyocytes using split-intein protein transsplicing. Proc. Natl Acad. Sci. USA 110, 15461–15466 (2013).
Rog-Zielinska, E. A., Norris, R. A., Kohl, P. & Markwald, R. the living scar--cardiac fibroblasts and the injured heart. Trends Mol. Med. 22, 99–114 (2016).
Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273–277 (2014).
Liao, S. Y. et al. Proarrhythmic risk of embryonic stem cell-derived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm 7, 1852–1859 (2010).
Tang, L. et al. Structural basis for Ca2+ selectivity of a voltage-gated calcium channel. Nature 505, 56–61 (2014).
Yue, L., Navarro, B., Ren, D., Ramos, A. & Clapham, D. E. The cation selectivity filter of the bacterial sodium channel, NaChBac. J. Gen. Physiol. 120, 845–853 (2002).
Corry, B., Lee, S. & Ahern, C. A. Pharmacological insights and quirks of bacterial sodium channels. Handb. Exp. Pharmacol. 221, 251–267 (2014).
Scheuer, T. Bacterial sodium channels: models for eukaryotic sodium and calcium channels. Handb. Exp. Pharmacol. 221, 269–291 (2014).
Blanchet, J., Pilote, S. & Chahine, M. Acidic residues on the voltage-sensor domain determine the activation of the NaChBac sodium channel. Biophys. J. 92, 3513–3523 (2007).
Shaya, D. et al. Structure of a prokaryotic sodium channel pore reveals essential gating elements and an outer ion binding site common to eukaryotic channels. J. Mol. Biol. 426, 467–483 (2014).
Arrigoni, C. et al. Unfolding of a temperature-sensitive domain controls voltage-gated channel activation. Cell 164, 922–936 (2016).
Deisseroth, K. Optogenetics: 10 years of microbial opsins in neuroscience. Nat. Neurosci. 18, 1213–1225 (2015).
Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).
Cho, H. C. & Marban, E. Biological therapies for cardiac arrhythmias: can genes and cells replace drugs and devices? Circ. Res. 106, 674–685 (2010).
Hu, T., Fu, Q., Chen, P., Zhang, K. & Guo, D. Generation of a stable mammalian cell line for simultaneous expression of multiple genes by using 2A peptide-based lentiviral vector. Biotechnol. Lett. 31, 353–359 (2009).
Klinger, R. & Bursac, N. Cardiac cell therapy in vitro: reproducible assays for comparing the efficacy of different donor cells. IEEE Eng. Med. Biol. Mag. 27, 72–80 (2008).
Badie, N., Scull, J. A., Klinger, R. Y., Krol, A. & Bursac, N. Conduction block in micropatterned cardiomyocyte cultures replicating the structure of ventricular cross-sections. Cardiovasc. Res. 93, 263–271 (2012).
Abbaci, M. et al. Gap junctional intercellular communication capacity by gap-FRAP technique: a comparative study. Biotechnol. J. 2, 50–61 (2007).
McSpadden, L. C., Kirkton, R. D. & Bursac, N. Electrotonic loading of anisotropic cardiac monolayers by unexcitable cells depends on connexin type and expression level. Am. J. Physiol. Cell. Physiol. 297, C339–C351 (2009).
Badie, N. & Bursac, N. Novel micropatterned cardiac cell cultures with realistic ventricular microstructure. Biophys. J. 96, 3873–3885 (2009).
Bursac, N., Aguel, F. & Tung, L. Multiarm spirals in a two-dimensional cardiac substrate. Proc. Natl Acad. Sci. USA 101, 15530–15534 (2004).
Protas, L. et al. Expression of skeletal but not cardiac Na+ channel isoform preserves normal conduction in a depolarized cardiac syncytium. Cardiovasc. Res. 81, 528–535 (2009).
Pitts, K. R. & Toombs, C. F. Coverslip hypoxia: a novel method for studying cardiac myocyte hypoxia and ischemia in vitro. Am. J. Physiol. Heart Circ. Physiol. 287, H1801–H1812 (2004).
Hodgkin, A. L. & Huxley, A. F. Propagation of electrical signals along giant nerve fibers. Proc. R. Soc. Lond. B 140, 177–183 (1952).
ten Tusscher, K. H., Noble, D., Noble, P. J. & Panfilov, A. V. A model for human ventricular tissue. Am. J. Physiol. Heart Circ. Physiol. 286, H1573–H1589 (2004).
Nygren, A. et al. Mathematical model of an adult human atrial cell: the role of K+ currents in repolarization. Circ. Res. 82, 63–81 (1998).
Hodgkin, A. L. & Rushton, W. A. The electrical constants of a crustacean nerve fibre. Proc. R. Soc. Med. 134, 444–479 (1946).
Rall, W. in Comprehensive Physiology John Wiley & Sons, Inc. (2011).
Shaw, R. M. & Rudy, Y. Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ. Res. 81, 727–741 (1997).
We thank A. Krol and C. Jackman for assistance with neonatal rat cardiomyocyte culture, N. Gillum and K. Kanagasegar for assistance with the development of computational model of BacNav, and L. Li for construction of lentiviral libraries. We further thank V. Bennett and L. You for critical reading of the manuscript. This work was supported by American Heart Association Predoctoral Fellowship PRE 16790012 to H.X.N. and National Institutes of Health grants HL104326, HL132389, HL126524 and HL126193.
The authors declare no competing financial interests.
Supplementary Figures 1-11 and Supplementary Tables 1-3. (PDF 4770 kb)
Action potential propagation in monolayers of E-HDFs expressing Kir2.1, Cx43, and NavRosD G217A. (MOV 8551 kb)
Action potential propagation in monolayers of E-HDFs expressing Kir2.1, Cx43, and NavSheP D60N. (MOV 5907 kb)
E-HDFs rescue impaired cardiomyocyte conduction in vitro. (MOV 7557 kb)
Regional ischemia in neonatal rat cardiomyocyte monolayer. (MOV 11516 kb)
About this article
Cite this article
Nguyen, H., Kirkton, R. & Bursac, N. Engineering prokaryotic channels for control of mammalian tissue excitability. Nat Commun 7, 13132 (2016). https://doi.org/10.1038/ncomms13132
Biotechnology Advances (2020)
PLOS ONE (2020)
Current Opinion in Biotechnology (2019)
Journal of Cell Science (2019)
Engineered cardiac tissue patch maintains structural and electrical properties after epicardial implantation